A cost-benefit evaluation of using propofol and alfentanil for a short gynecological procedure.
It is well established that the immediate recovery after propofol or alfentanil anesthesia is short. Although the drugs themselves are more expensive than older drugs, a potential for saving costs arises. Concerning the benefits in terms of late recovery, less information is available. With vaginal termination of pregnancy (VTP), anesthesia is supposed to be the major cause of sick-leave. Does propofol and alfentanil anesthesia for VTP reduce sick-leave compared with thiopental and nitrous oxide anesthesia, and do the increased costs of the drugs outweigh the reduced costs of sick-leave? Data were obtained from 39 of 40 patients in ASA class I accepted for VTP and allocated to either propofol and alfentanil anesthesia (PA) or thiopental and nitrous oxide anesthesia (TN). A questionnaire was filled in by the patients at home after regaining full fitness. The number of patients with a sick-leave of 2 days or less in the groups was compared statistically with the number of patients with 3 days or more off work. The economic impact from the reported sick-leave was calculated for each study group, using data from national statistics. The figures were compared with the calculated costs of the drugs. The median number of days of sick-leave was 1 in the PA-group and 2 in the TN-group (range 0-3 and 0-5, respectively). Nineteen of the 20 patients in the PA-group and 13 of the 19 patients in the TN-group needed a short sick-leave period of 2 days or less (one-sided test of proportions, P < 0.05). At the time of the study each patient was paid 210 SEK/day from the social insurance system and the mean cost of the drugs was 72 and 15 SEK/patient in the PA- and TN-groups, respectively. Using the mean difference in sick-leave between the groups of 0.8 days/patient (rather than the difference in median values of 1), a net gain of 111 SEK/patient was the result of changing from thiopental-nitrous oxide anesthesia to propofol-alfentanil anesthesia. Although the cost of drugs was higher, costs for the social insurance system and for the individuals themselves were reduced by almost 50%, when using the propofol and alfentanil combination, resulting in an overall benefit corresponding to almost twice the increase in the cost of anesthesia.
Enlund
M
M
Department of Anesthesia and Intensive Care, Central Hospital, Västerås, Sweden.
Kobosko
P
P
Rhodin
A
A
D000028:Abortion, Induced; D000293:Adolescent; D000328:Adult; D015760:Alfentanil / Q000494:pharmacology*; D000758:Anesthesia / Q000191:economics*; D018686:Anesthetics, Intravenous / Q000494:pharmacology*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D011247:Pregnancy; D015742:Propofol / Q000494:pharmacology*
D018686:Anesthetics, Intravenous; D015760:Alfentanil; D015742:Propofol